Veterinary practices are being urged to raise awareness of summer skin conditions, such as sweet itch, following research carried out by Elanco Companion Animal Health, distributor of Cavalesse, which revealed that vets only tend to be consulted after horse owners have tried to manage the condition themselves (73%), or if the clinical signs have become severe (67%), potentially leading to major welfare implications.
According to the research, this is despite the fact that over half (55%) of owners of a horse with sweet itch showed concern that their horse will suffer, and nearly half being stressed about the way the condition will affect it (47%). While many horse owners are fairly knowledgeable about the causes of sweet itch and its clinical signs, over a quarter of respondents (26%) did not start managing the condition before the midge season in the spring, which may make managing the condition more frustrating. Nearly a third (31%) stated that they had to curtail their activities with their horse due to welfare, aesthetic and behavioural issues, such as head shaking, rubbing, unpredictability and aggression.
Ed Whittle, technical consultant at Elanco Companion Animal Health said: "86% of those questioned considered sweet itch to be a very serious welfare issue if left untreated, with the worst aspects of the condition being the suffering and distress caused by the constant irritation which affects the quality of life of the horse. Over half (55%) felt that sweet itch had adversely affected the behaviour of their horse, making them difficult to handle or ride. Veterinary practices should be proactively talking to their clients about summer skin conditions such as sweet itch to help alleviate the suffering and distress caused by this frustrating disease."
Elanco says it will be joining forces with the British Horse Society (BHS), The Blue Cross, The Horse Trust, Redwings Horse Sanctuary and World Horse Welfare (WHW) to raise awareness of summer skin conditions, such as sweet itch, during Sweet Itch Awareness Month (SIAM) in March. The campaign will highlight the preventative measures that should be carried out to help alleviate sweet itch and the importance of management of the condition before the start of the midge season in the spring.
Lee Hackett, head of welfare at the BHS, said: "The results of this survey show just how important raising awareness of sweet itch is. All of us, whether we are welfare organisations or vets, need to play our part in educating owners about sweet itch in the hope that they will seek expert advice at an earlier stage and reduce the number of horses that suffer as a result of this condition."
Kerry Taylor, education officer at The Blue Cross, said: "The Blue Cross is pleased to be supporting the sweet itch campaign to raise awareness of the physical and mental impact this condition has on horses. During our May 2011 National Equine Health Survey, skin problems came out the top syndrome affecting horses, and we continue to see many horses coming into our care suffering from sweet itch. Prevention and early treatment is key to managing the potentially debilitating condition."
For further information on sweet itch, Sweet Itch Awareness Month or Cavalesse, please visit http://www.fidavet.com/, or contact Elanco Companion Animal Health, Lilly House, Priestley Road, Basingstoke, RG24 9NL, 01256 353131.
Reference
Sweet itch - effect on horse and owner. Mo Gannon & Associates. Web survey in November 2011. 351 responses - owners who have owned horses with sweet itch in the last two years.
Pfizer Animal Health has launched a dedicated Equine Business Unit to provide a higher level of service and a comprehensive range of products to equine vets across the UK.
Created following the merger with Fort Dodge, the Pfizer Equine Business Unit is headed by Ben Lacey MA Vet MB MRCVS, who has previously held both technical and sales roles at Pfizer. Ben and his team have a brief to offer a breadth of product, support and flexibility not previously available to equine vets.
The product range offered by the Pfizer Equine Business Unit includes the Equest range of parasiticides; the Duvaxyn vaccines for Equine Herpes Virus, West Nile Virus and Rotavirus and products such as Equimidine and Torbugesic. Also offered are existing Pfizer brands such as the Equip vaccine range, the antibiotic Excenel Sterile Powder, the NSAID Rimadyl for Horses and Depo-MedroneV.
Five experienced account managers with a strong track record in the equine sector have been appointed by Pfizer to build relationships with equine vet practices on a regional basis. They are:
South East England Mark BakerWest Midlands, Cheshire, Wales Laurie MayEast Anglia, East Midlands Penny McCannSouth West, South Wales Anna CunninghamThe North, Scotland Alexandra Cox
Ben Lacey said: "Building our new team and combining the highly regarded products offered previously by both Fort Dodge and Pfizer has proved a stimulating process. We've also worked closely with many of our existing practice customers to look at how we can develop the service we provide to them.
"We're now able to offer a product range which I believe is unrivalled in the market and a highly committed team of equine professionals, who share a vision and passion for equine health. We're looking forward to building our business with both existing and new customers in the months ahead."
The webinars each last between three and five minutes and are part of the 2016 ‘Talk About Laminitis’ disease awareness initiative to help detect, manage and monitor PPID.
The webinars can be viewed on the Boehringer Academy website – www.boehringer-academy.co.uk - and podcast versions are also available enabling veterinary professionals to listen to them ‘on the go’.
The first series includes:
The second webinar series covers:
For further information on the webinars or podcasts visit www.boehringer-academy.co.uk or contact your local Boehringer Ingelheim territory manager.
The new online resources have been compiled by BEVA in collaboration with the RSPCA, World Horse Welfare, the SSPCA and the National Equine Crime Group, together with national Police and Local Authority representatives.
BEVA President Imogen Burrows said: “It can be an intimidating process when visiting an equid without an owner, but our new resources aim to address the potential stress factor and make the rules around the provision of care very clearcut.
“We have produced all the documents the attending vet should need, no matter their location or circumstances.
"Most importantly, if they are attending alone, they will know how to access the right help at the right time, secure in the knowledge that they are following appropriate, validated procedures.”
The resources include a decision tree for quick checking correct procedures, an overview of stakeholder roles and responsibilities, a ‘what if’ section for troubleshooting and an essential contacts registry.
There are also examination and treatment worksheets, and euthanasia certification forms.
Imogen added: “We have put significant thought and effort into producing these new resources, especially from an ambulatory veterinary perspective.
“It should make all the difference for vets, knowing that they have the all the information they need, to hand, In the unlikely event of a callout to an equid of unknown ownership.”
https://www.beva.org.uk/Resources/Clinical-resources/Welfare-toolkit/Managing-equids-of-unknown-ownership
Centaur has launched a new service on the MyCentaur website which allows for 24-hour ordering from any broadband enabled computer.
A secure practice shopping list with controlled staff access to ordering and management information enables practices to safely control any buying.
According to the company, a key feature of the website is that any orders placed on line by 9pm will be delivered the following day, which gives practices even greater flexibility on ordering times over any existing vet wholesaling ordering service. As well as greater convenience, a financial benefit in using this method of ordering is that all on-line orders attract an additional two per cent discount.
The company says that so far, it has had no cases of flu reported in horses vaccinated with Equip F or Equip FT in the UK. However, it cautions that in the present flu outbreak it is not clear if any of the current influenza vaccines will provide complete clinical protection against the mutated strain.
In addition, Zoetis highlights that:
Equip F and Equip FT are both indicated for reduction in clinical signs caused by Equine Influenza, including Florida Clade 1 strains.
Cross protection has been demonstrated by virulent challenge for representative strains of Florida Clade 1 (Paillot et al 20081, Bryant et al 20102) and Clade 2 (Paillot et al 20153).
Vaccination with Equip F stimulated a flu specific cell-mediated immune response to a Clade 1 strain which was detectable for up to one year after the third vaccination in primary course (Paillot et al 20153).
Zoetis says it is confident that the Equip range continues to be effective against its licensed indications.
If you have further questions about the vaccines, ring 0845 300 8034 and choose option 1 to speak to Zoetis' technical team.
References
BEVA Congress 2021 will now take place from September 4th-7th 2021.
The decision to cancel Congress 2020 was taken by BEVA Council and the Congress programme committee because of the unpredictable circumstances of the coronavirus pandemic.
Tim Mair, President of BEVA said: “The overriding factor in our decision-making process was to protect everyone attending Congress. We are chartering unknown territory at the moment and the additional planning requirements needed to run a large event like BEVA Congress with social distancing measures in place will take time.
“We intend for September 2021 to mark an exciting, fresh start for the profession following the harrowing experiences of 2020. It should be safe for our international speakers and delegates to attend by then, getting us all back on track with networking and world-class CPD to inspire us for the new post Covid-19 world.”
Tickets for BEVA Congress 2021 will be available later this year, more information from: www.bevacongress.org.
Preliminary results, which recorded a decline in the quantities of antimicrobials prescribed from 2014 to 2018, were published in 2022.
A further audit has now been undertaken in all 22 of the company's first opinion practices to investigate the age, breed and estimated weight of each horse, the clinical indication for antibiotic use, the drugs prescribed, their dose rates, the route of administration and whether culture and sensitivity were used to guide antimicrobial selection.
Data collection was completed in August 2022.
This secondary audit was conducted using a ‘point prevalence’ survey, in which each CVS Equine first opinion Quality Improvement Lead gathered information about all systemic antibiotics prescribed by each of their practices on one day a month for 12 consecutive months.
The project yielded information on 331 cases where systemic antimicrobials were prescribed.
Complete data about the first line-drug selection were available for 261 prescriptions.
The commonest prescribed antimicrobial was sulfadiazine/trimethoprim (41%), followed by oxytetracycline (23%), procaine penicillin (16%), doxycycline (13%), gentamicin (4%), metronidazole (1%), ceftiofur (1%) and enrofloxacin (1%).
Highest priority critically important antimicrobials (ceftiofur and enrofloxacin) were only prescribed in four horses (clinical indications for these included possible sepsis, skin infection, lower respiratory tract infection and a wound complication – in none of these cases was the first-line drug selection based on the results of culture and sensitivity.
Overall, the clinical indications for antimicrobial use were recorded in 246 cases; the commonest indications were cellulitis/lymphangitis (27%), uncomplicated wounds (19%), surgical prophylaxis (15%), respiratory infections (11%) and skin infections (8%).
Hattie Lawrence, Director of CVS Equine, said: “Though the impact of this work is yet to be documented, there is anecdotal evidence that it has raised awareness amongst our veterinarians of the importance of antimicrobial stewardship.
"Taken together, the results of both pieces of work will be used to help develop and inform clinical audits and clinical guidelines of antimicrobial use in horses.”
Thus far, the hospital has relied on conventional radiographs or referred for MRI for the bulk of its distal limb imaging.
The new Hallmarq standing CT scanner provides information that surpasses the capabilities of radiography, while also reducing radiation exposure to the patients and staff.
The scanning process is also considerably quicker, enabling prompt diagnosis and treatment planning.
Tom McParland, Valley Equine Hospital’s surgeon said: "We are confident that this diagnostic modality will significantly enhance our ability to identify not just thoroughbred fetlock pathology earlier but improve our diagnostic abilities of the distal limb for all our equine patients, racing and leisure alike.”
Valley Equine Hospital says it chose the Hallmarq standing CT scanner due to its ability to scan using just standing sedation which ensures a safer and more efficient experience for the horses compared to general anaesthesia.
www.valleyequinehospital.co.ukinfo.hallmarq.net/focus-on-the-foot
Squamous cell carcinoma affects horses’ genitalia, eyes, or skin around the eyes. The tumours typically have a guarded to poor prognosis, and the therapeutic approaches available have variable success rates. Euthanasia on welfare grounds is necessary in a significant number of cases.
Before this new research was published, pathologists and researchers Dr Alejandro Suárez-Bonnet and Professor Simon Priestnall, both from the RVC, had already undertaken research which showed that equine squamous cell carcinoma affecting the penis frequently acquires the ability to degrade the extracellular matrix and become much more biologically aggressive2. This is known as ‘epithelial to mesenchymal transition’.
This new study, recently published in Scientific Reports, is the product of a multi-institutional effort, which used both “classical” anatomic histopathology assessment and artificial intelligence to demonstrate a correlation between chronic inflammation, equine papillomavirus infection and progression of equine penile squamous cell carcinoma.
Several additional cancer-related signalling molecules, which are important in researchers’ understanding of human penile cancer, were also studied and the results obtained will lead to a much better understanding and treatment of the cancer.
Simon Priestnall, Professor of Veterinary Anatomic Pathology at the Royal Veterinary College, said: “Equine squamous cell carcinoma is the second most common type of cancer in horses, with a variable prognosis, so we are delighted to have made this breakthrough that provides a greater understanding and can lead to more effective treatments for horses and their owners.
"The RVC has always recognised the value of collaboration, and Alejandro and I enjoyed working alongside the teams at KCL, the University of Edinburgh and UCL. This project shows what can be achieved when different organisations work together with a common aim and we hope the similarities between the tumour in horses and people can offer a true One Health benefit."
Dr Alejandro Suárez-Bonnet, Lecturer in Comparative Pathology at the Royal Veterinary College, said: "I am so pleased with the results of this study, which will hopefully pave the way for improved prognosis of horses diagnosed with equine squamous cell carcinoma.
"Our work is not over, however. Thanks to the help of a grant from the Horse Race Betting Levy, Simon and I are leading a Master’s degree project investigating equine penile, ocular and vulvar squamous cell carcinomas from a broader perspective.
"Our hope is to identify if variability exists between equine papillomavirus infectious status, morphological and microscopic difference, and cancer progression, with the aim of identifying potential therapeutic targets as well as diagnostic markers with prognostic implications for maximum benefit to the British equine population.”
A DNA test which will save foals from unnecessary pain and suffering, and ultimately death, has been launched by the Animal Health Trust.
Foal Immunodeficiency Syndrome (FIS), a genetic disorder which is known to affect Fell and Dales ponies, causes foals to become anaemic and prone to opportunistic infections. Any foal born with the syndrome will not survive.
The new diagnostic DNA test, which costs £40, is the result of ten years of research by the Animal Health Trust (AHT) and the University of Liverpool. The test will not only identify foals which have the fatal condition but will highlight adult ponies who are carriers of the genetic trait which causes the syndrome. Affected foals will be prevented by avoiding covering a carrier mare with a carrier stallion.
Owners and breeders who wish to find out the genetic status of their ponies can arrange for a simple pulled mane or tail hair sample to be taken by a vet and submitted to the AHT. The Fell Pony or Dales Pony Societies will supply sample bags for submission on request. A fast-track system to identify foals suffering with the condition will report results within three working days.
The team that developed the DNA test was led by the AHT's Dr June Swinburne and Professor Stuart Carter of the University of Liverpool with research student Laura Fox-Clipsham. They believe that by using the test, owners and breeders will eventually be able to eradicate this awful condition.
Dr. June Swinburne, said: "The DNA test gives owners and breeders the power to overcome this devastating illness. It enables them to make informed decisions about which ponies to breed. We have already had samples submitted by HM The Queen from her own breeding stock of Fell ponies. I'd urge any breeders of Fell or Dales ponies to submit samples in order to arm themselves with the facts they need to prevent the birth of affected foals and thereby avoid this distressing condition."
Professor Carter, said: "The research, and ultimately the DNA test, has only been possible thanks to funding from The Horse Trust and the support of the Fell Pony Society and the Dales Pony Society who have supplied DNA samples. We consider that the efforts of all involved in enabling this research have lead to a major advance in animal welfare."
For more information on testing, contact the Fell or Dales Pony Societies. Alternatively visit the AHT website http://www.aht.org.uk/genetics_fis.html or email FIStesting@aht.org.uk
The Seller’s Declaration has been revised with the support of British Equestrian (BEF) and British Horse Society (BHS) to make the purchase process more efficient for both buyer and seller.
BEVA says the new Declaration is a more extensive, stand-alone document which the buyer should request from the seller directly before the formal process of the PPE commences.
In this way the seller is obliged to disclose any pertinent information, such as previous lameness, stereotypies, specific management requirements, previous veterinary interventions and details of preventative dental care and worm control, prior to the PPE proceeding.
Lucy Grieve, Veterinary Projects Officer at BEVA, said: “BEVA’s new Seller’s Declaration will iron out the PPE process to make it smoother and more efficient for all three parties involved: buyer, seller and vet.
“The advantage is it cuts out the vet as a middleman… asking if the horse has received any medication, or coughs on dry hay and so on.
“The new Seller’s Declaration means that the seller should declare those things to the buyer straight off.
"If completed in advance, it should give the buyer more robust information on which to base proceeding with the PPE or not.”
https://www.beva.org.uk/Resources/Clinical-resources/PPE-toolkit
Last year BEVA received a national Antibiotic Guardian award from Public Health England in recognition of its work to promote responsible use of antibiotics. It was the only organisation from the veterinary profession to be shortlisted. BEVA launched its Protect ME antimicrobial campaign in 2012 to coincide with European Antimicrobial Awareness day. The Association has launched additional resources each year to facilitate compliance and educate the public about the importance of antimicrobial awareness.
This year, to recognise World Antibiotic Awareness Week (16th to 22nd November, 2016) and European Antibiotic Awareness Day (18th November), BEVA is encouraging members to document their efforts to reduce the use of critically important antibiotics.
To enter for the award, veterinary surgeons need to share practice sales data (in mls) of chosen antibiotics. Practices that document a reduction in antibiotic sales of these drugs will be presented with a BEVA Antibiotic Champion Award to endorse their commitment to responsible use of antibiotics and to help promote public awareness of the campaign. Members are also encouraged to sign up to be antibiotic guardians at www.antibioticguardian.com
Gayle Hallowell, Co-Chair of the BEVA Health and Medicines Committee said: "We are extremely proud of the equine veterinary profession’s commitment to the responsible use of antibiotics. We hope the introduction of our Champion Award will inject new vigour into efforts to continue to reduce the use of our precariously limited antibiotic resources."
To apply for BEVA Antibiotic Champion Award status visit http://www.beva.org.uk/Antibiotic-Champion-Award The BEVA Protect ME toolkit is free to BEVA members and can be downloaded at www.beva.org.uk.
The British Equine Veterinary Association (BEVA) welfare award 2008, sponsored by The Blue Cross, has been presented to the Retraining of Racehorses (RoR) organisation for their contributions to equine welfare in support of the re-training and re-homing of racehorses.
The award, which was introduced by BEVA in conjunction with The Blue Cross animal welfare charity eight years ago, is a formal recognition of significant contributions made by veterinary surgeons and others to equine welfare.
It was presented to Ron Huggins, trustee of the ROR and an owner and breeder of racehorses, at the 47th BEVA Annual Congress in Liverpool on Friday 12 September 2008, by Kerstin Alford, equine welfare director of The Blue Cross.
Kerstin said: "The financial support that RoR provides for charitable racehorse rehabilitation centres, together with their education programme to help owners and riders of former racehorses, make them very worthy recipients of this award."
Di Arbuthnot, director of operations said: "RoR are delighted to receive this prestigious award to recognise the work the charity does for former racehorses to provide them with a life after racing."
Retraining of Racehorses was established in 2000 by the British Horseracing Authority. Its aim is to raise funds from the British racing industry to provide and maintain facilities for the care, retraining and rehoming of former racehorses. Under the direction of the chairman of the trustees Peter Deal, the RoR has become recognised as a vital component of the racing industry.
The Blue Cross was founded in 1897 to care for working horses on the streets of London, and equine welfare still plays a vital role in its work today. The charity rehabilitates and rehomes over a hundred horses and ponies every year at its equine centres in Burford (Oxon) and Rolleston-on-Dove (Staffordshire). A third facility in Northiam (East Sussex) provides rest and retirement for Blue Cross equines.
The first steps have begun to find Petplan and The Veterinary Business Journal's Practice Manager of the Year for 2012.
Nominations are now being sought for the most accomplished UK practice managers and recommendations are welcome from any member of the veterinary team.
Three finalists will be chosen and the winner announced at the annual Petplan Veterinary Awards in April 2012.
Robin Fearon, editor of the Veterinary Business Journal, said: "It is a distinct pleasure to launch the awards programme each year knowing that at the end of it we will be able to announce another winning practice manager.
"These awards are so important in promoting the role and highlighting the crucial part that managers play in practice strategy and success - we can't wait to see your nominations."
Judges will assess candidates' applications and choose the three finalists based on their competency in areas such as staff development, financial strategy and marketing initiative.
Last year's winner Denise Coston is practice manager at Castle Veterinary Surgeons in County Durham. She said: "Winning this award has meant a lot to me because it makes you feel valued. I would say to anyone thinking of nominating their practice manager: 'just do it'.
"The role of practice manager varies in each practice and can be hard to quantify with specific measures, but it means a lot to celebrate someone getting it right. It is an excellent way to promote the role of practice manager and it is great to get recognition alongside vets and nurses."
This award is supported by the Society of Practising Veterinary Surgeons and the Veterinary Practice Management Association.
As well as a plaque commemorating their achievements, the winner will once more receive one year's free membership to the VPMA.
Nominations for this year's award close on 10 February 2012. Application packs are available from: Jackie Morrison, The Veterinary Business Journal, Olympus House, Werrington Centre, Peterborough PE4 6NA, or e-mail jackiemorrison@vbd.uk.com.
Alternatively visit www.vetsonline.com/ to download yours direct.
From early 2025, all vets, nurses and technicians will be required to wear a hard hat in the vicinity of a horse, pony or donkey – whether in practice, on a yard, or at a client’s premises.
It follows a three-year research project collaborating with the University of Liverpool which revealed that 90% of veterinary clinicians have experienced an injury during their career.
It is hoped that the move will reduce injuries to the head – one of the most common traumas to be suffered by equine vets identified by the research, usually sustained when examining distal limbs. CVS says that in the US, equine vets sustain on average eight serious injuries during their career, making it the second highest profession for non-fatal injuries.
The University of Liverpool research found that over 25% of equine vet injuries have led to hospital attendance. Dr. John Tulloch, Lecturer and European Specialist in Veterinary Public Health at the University of Liverpool, who led the research, said: “Vet visits are not an ‘everyday activity’ for a horse.
"As a result, many horses will be on heightened alert, and some may be more prone to unpredictable behaviour. “Vets are often in a vulnerable situation when examining a horse.
"And it’s difficult to pick up on a horses’ signals, especially when examining areas such as distal limbs. “Our research found that many injuries happen when a horse kicks or pushes a person over and the person’s head makes impact with the ground.
"So, wearing a hard hat will be a big step towards preventing traumatic head injuries if this were to happen.” Sophie Ignarski, Equine Director at CVS said: “All of our clinicians are at risk in their day-to-day work – whether they are newly qualified or very experienced.
"Other colleagues including nurses, vet techs and patient care assistants are similarly vulnerable. “We decided to make wearing of hard hats mandatory in order to protect all of our colleagues and minimise the potential risk of head injury, understanding it can never be fully eliminated.
"We recognise that this policy shift represents a degree of change but hope that it serves to further support and progress the equine veterinary industry more widely. “Our policy is evidence-based, utilising three years of rigorous research, and we will continue our efforts in the future to grow our knowledge and understanding of this important area.
"By doing so, we join other industries – such as construction – who have already adopted similar changes to the extent they are now established in their culture.”
https://www.sciencedirect.com/science/article/pii/S0167587725001266
In the trial, published in the Equine Veterinary Journal, synovitis was induced in the right intercarpal joint of 24 horses by intra‐articular injection of 0.5 ng lipopolysaccharide (LPS) of Escherichia coli. After intra‐articular challenge, the nutraceuticals resulted in significantly lower synovial fluid TP, TNCC and PGE 2 compared with placebo, leading the authors to conclude that: "The preventive administration of these nutraceuticals showed anti‐inflammatory effects in this validated synovitis model."
Dr Maarten Oosterlinck DVM, PhD, Dipl. ECVS, one of the authors of the study, said: "Nutraceuticals are often used in the management of osteoarthritis, which is a common cause of chronic lameness in horses but their 'curative' efficacy remains controversial and the quality of the relevant studies is generally low. We set out to evaluate ArtiTec in a well-designed and controlled study. Our research shows that ArtiTec significantly decreased joint inflammation and could be useful in preventing the onset of arthritis."
Cavalor also points to a further field trial of the product by vets in Belgium which showed that it improved lameness in 74% of cases.²
ArtiTec contains glucosamine, MSM, chondroitin, hyaluronic acid, blackcurrant extract, feverfew and pineapple, turmeric root and Boswellia Serrata.
Lieselot Hamerlinck, managing partner at Cavalor said: "Joint supplements account for 34% of the equine supplement market so we know how important these products are to horse owners. Cavalor ArtiTec is the result of an extensive research and development programme and its anti-inflammatory effect has been documented in both scientific studies and a field trial. It can also be used in combination with our other joint supplements, Arti Matrix and Arti Base."
For more information, contact Zebra Products on 01352 763350.
Ceva Animal Health has produced a leaflet to help horse owners understand the cause, diagnosis and management of equine back pain.
The company says the management of back pain in the horse can be a particular challenge to vets and a source of frustration for owners. Early diagnosis is likely to be associated with a more favourable outcome but it's important to ensure that other causes of pain and poor performance such as lameness, are not contributing to the horse's clinical signs.
'Understanding back pain' explains the anatomy of the back, as well as the clinical signs of back pain, and how it is diagnosed, including the treatment options and the general prognosis. Copies of the new leaflet are available, free of charge, from your Ceva sales representative. Leaflets on 'Understanding bone spavin', 'Understanding navicular disease', 'Understanding sacroiliac disease' and 'Equidronate discharge instructions', are also available.
For further information contact your local Ceva representative or Ceva Animal Health Ltd, Unit 3, Anglo Office Park, White Lion Road, Amersham, Bucks, HP7 9FB, Telephone +44 (0) 1494 781510.
The Equine Veterinary Journal (EVJ) has published a free online collection of articles which explain the current understanding of equine antimicrobial resistance and how the profession can preserve the effectiveness of these essential medicines.
The new collection comprises ten clinical reports and studies and three editorials covering current trends on bacterial populations, risk factors and the appropriate use of antimicrobials in practice.
A clinical report on the changes in bacterial populations in foals with sepsis raises the question whether the emergence of resistance in horses has occurred as a result of antibiotic use in humans, with nosocomial spread from human handlers in foals. Studies on the prevalence of faecal carriage of antimicrobial resistant E. coli show their prevalence to be common in normal horses in the community in the UK, although MRSA carriage was rare. Data suggested transmission of resistant bacteria from animals receiving antibiotics may result in carriage of bacteria by in contact animals.
The need for judicious use of antimicrobials is reinforced in a study on antimicrobial-associated diarrhoea in three equine referral practices. Two papers investigate both prescribing practice in the UK and the impact of antimicrobial use on infection and pyrexia in hospitalised horses, concluding that there are opportunities for more targeted, ‘smart’, use antimicrobials in the perioperative period, rather than simply more antimicrobials.
The final study discusses a low-cost syndromic surveillance model for monitoring healthcare associated infection in clinical practice to provide a realistic benchmark against which other hospitals may compare antimicrobial study data.
Three supporting editorials complete the online collection, giving comment on the overall situation of antimicrobial resistance in the horses, including the current political situation and antimicrobials and surgical site infection.
Professor Peter Clegg, Associate Editor of the Equine Veterinary Journal said: "It remains to be determined how big a problem antimicrobial resistance will become for the equine veterinary profession, either through greater difficulties in treating horses, or through political pressure to restrict access to antimicrobials. Meanwhile the EVJ remains committed to the promotion of responsible stewardship to best preserve the efficacy of the drugs we have got for as long as we can."
Mark Bowen, President of the British Equine Veterinary Association and guest editor said: "BEVA has a long-term commitment to promoting responsible antimicrobial use throughout the profession and supporting EAAD through the PROTECT ME brand. This year we have released resources around Education, aimed at the profession through EVJ and to the horse owning public through development of material that can be provided alongside antimicrobial dispensing. The work of the equine profession in preserving the highest priority antimicrobials will ensure efficacy can be retained for as long as is possible."
The antimicrobial online collection is available free online at: http://onlinelibrary.wiley.com/journal/10.1001/(ISSN)2042-3306/homepage/antimicrobial_resistance.htm
The new resources include:
Celia Marr, chair of BEVA’s infectious disease working group, said: “Equine disease prevention and management are fundamental for responsible equine health, welfare and performance.
“These resources cover the need-to-know information and are all in one easy reverence location on the newly designed infection control page on the BEVA website.”
https://www.beva.org.uk/Resources/Equine-infectious-diseases
BCF, Instrumentation Concept and VetSonic have collected 'VetSurgeon.org Best Stand Awards'; the first two at BEVA Congress and the latter at BCVA Congress.
Judging for the BEVA Congress awards was undertaken by members of BEVA Council. BCF picked up the Best Large Stand Award which was presented by outgoing President, Andrew Harrison.
Pictured left to right: BEVA President, Andrew Harrison, Gavin Mitchell and Carole Irvine of BCF, and John Alborough representing VetSurgeon.org.
Instrumentation Concept picked up the Best Shell Scheme Award
Pictured left to right: Outgoing BEVA President, Andrew Harrison; Tahir Afzac of Instrumentation Concept; John Alborough representing VetSurgeon.org, and Sheraz Ishaque of Instrumentation Concepts
At BCVA Congress, Vetsonic won the Best Stand Award.
Pictured left to right: Clare Walsh, Vetsonic Director; John Alborough, All Round Good Egg representing VetSurgeon.org; Gareth Hateley, then President BCVA and Sarah Vermont, Marketing Manager Vetsonic.
A research project funded by The Horse Trust has found that various types of ocular tumours can be successfully treated with mitomycin C, a cytotoxic antibiotic isolated from a bacterium.
The research concludes that mitomycin C offers a safe and cost effective alternative to current treatment options such as surgery and radiation.
The research project was led by Fernando Malalana, while working as The Horse Trust's Clinical Scholar in Equine Internal Medicine at University of Liverpool. Fernando is now working as a Clinician Teacher in Equine Internal Medicine at the university.
Ocular tumours are more difficult to treat than tumours in other parts of the horse's body due to the risk of damaging the eye. In the study, Malalana investigated the use of mitomycin C in treating ocular squamous cell carcinoma, the most common ocular tumour in horses, and occular sarcoids, skin tumors that frequently affect the eyelids .
Mitomycin C is an antibiotic isolated from a bacterium, Streptomyces caespitosus. It is known to have cytotoxic effects and has been used to treat tumours in horses before, but only in combination with surgery.
Currently, the main method of treating ocular squamous cell carcinoma is by removing the tumour surgically or with radiation. Both treatments are costly and have a number of associated risks. There is also the risk of damage or scarring to the eye.
Fourteen horses with ocular squamous cell carcinoma, three of which were affected bilaterally, were included in the study. Mitomycin C was applied to the conjunctival sac of the affected eye; in some of the cases the treatment was combined with surgery. Malalana found that of the 8 eyes treated with mitomycin C alone, clinical resolution occurred in 6 cases. Of the 9 eyes treated with both surgery and mitomycin C, clinical resolution occurred in 7 cases.
Mitomycin C was also used to treat various types of sarcoids found in the eye. Currently, the most effective treatment for occular sarcoids is radioactive wire. However, radioactive wire treatment is not ideal as it is expensive, only offered in two locations in the UK, and has potential health risks to the vet applying the wire due to exposure to radioactivity.
Six horses and two donkeys with occular sarcoids, including one horse that was affected bilaterally, were treated with mitomycin C, which was injected directly into the tumour. Malalana found that of the nine nodular and fibroplastic occular sarcoids treated with the antibiotic, all were completely cleared. However, the vets did not have good results with verrucous sarcoids.
Malalana said: "The results of this research should offer hope to the owners of horses that have eye tumours. We have already been contacted by vets from across Europe to find out more information about this treatment and hope that it will be offered to more horses with occular tumours in the future".
Vets at the University of Liverpool are now testing the use of mitomycin C on other tumours that are difficult to treat surgically, including melanomas near the horse's anus. So far, two cases have been treated, but it is too early to tell whether treatment has been successful.
Malalana's research has been submitted to Veterinary Ophthalmology journal.
Ceva Animal Health has introduced an improved version of Hepatosyl, its liver support supplement for horses.
Hepatosyl Plus for horses contains the same antioxidant ingredients as the original version but now also contains Silybin, the most active isomer of Silybum marianum (milk thistle)1.
According to Ceva, the addition of Silybin gives new Hepatosyl Plus a triple antioxidant approach to liver support to help neutralise free radicals within the liver. Free radicals are produced by hepatocyte mitochondria and cause oxidative damage to cell membranes, protein and DNA.
The company says Hepatosyl Plus's triple approach includes S-adenosylmethionine (SAMe), in a stable, pure and absorbable form, which is converted into the potent liver anti-oxidant glutathione and also helps to maintain bile flow; Vitamin E, which is well-known as a potent liver antioxidant, and Silybin, which works as an antioxidant by increasing cellular superoxide dismutase.
Hepatosyl Plus remains the only liver supplement to contain Vitamin K which is needed by the liver for the production of many essential clotting factors, such as factors II, VII, IX and X, making it ideally suited for pre and post anaesthetic liver support.
Ceva says an independent trial2 on horses with confirmed liver disease has demonstrated the benefits of Hepatosyl. Conducted by European Specialist in equine internal medicine Dr Tim Brazil, the trial involved seven horses of various ages and types. All animals were given Hepatosyl in addition to treatment with antimicrobials, corticosteroids, a low protein diet and vitamin B supplementation. Post SAMe supplementation tests revealed a notable reduction in raised liver enzymes, serum proteins and bile acids and the seven horses showed obvious improvements including better appetite, weight gain and demeanour.
For further product information contact Ceva Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG, telephone 01494 781510 or visit the website at http://www.ceva.uk.com/
References1 Flatland B (2003) Botanicals, Vitamins and Minerals and the Liver2 Brazil T (2007) S-adenosylmethionine liver support supplement trial in horses
Novartis Animal Health Inc. has completed an agreement with Luitpold Pharmaceuticals, Inc. that grants marketing rights for Adequan® Equine to Novartis in all major equine markets outside the U.S. The first launch of Adequan® Equine by Novartis will take place in Canada in June.
Adequan® Equine is indicated for treating joint dysfunction and lameness in horses caused by injury or degenerative problems. It is available for intramuscular and intra-articular administration. Adequan® is also indicated for treating joint dysfunction and lameness caused by injury or degenerative problems in dogs.
Mickey McDermott from Novartis' Communications Dept told VetSurgeon that the timing of Adequan's arrival in the UK depends on how long it takes to complete the registration transfers, but that the company hopes it'll be before the end of the year.